Skip to main content

Table 2 Univariate Logistic analysis for pCR of BC cancer after NAC

From: A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy

Factors

Univariate analysis

OR

95%CI

P

Lower

Upper

Age (Years)

≥ 44.5 vs<44.5

0.50

0.20

1.26

0.141

Menarche age (Years)

≥ 13.5 vs<13.5

0.61

0.29

1.28

0.191

Menstrual states

Menopausal vs. Premenopausal

0.87

0.37

2.04

0.743

Menopausal age (Years)

≥ 51.5 vs<51.5

2.96

0.94

9.34

0.064

Primiparous age (Years)

≥ 22.5 vs<22.5

0.60

0.29

1.28

0.187

Number of births

≥ 3 vs<3

0.50

0.18

1.39

0.184

cT

3/4 vs. 1/2

0.96

0.36

2.52

0.930

cN

2/3 vs. 0/1

1.36

0.59

3.14

0.473

cM

1 vs. 0

1.44

0.23

9.00

0.695

Axillary lymph nodes

Positive vs. Negative

2.12

0.73

6.22

0.169

Pathological type

Other vs. IDC

1.68E + 09

0.00

 

0.999

Grade

3 VS 1/2

2.96

1.09

8.05

0.033

ER

Positive vs. Negative

0.44

0.20

0.95

0.037

PR

Positive vs. Negative

0.60

0.28

1.29

0.194

HER-2

Positive vs. Negative

1.94

0.73

5.14

0.181

Ki-67

≥ 42.50 vs<42.50

1.96

0.92

4.20

0.082

Molecular classification

Triple negative vs. HER-2+ vs. Luminal B(HER-2+) vs. Luminal B(HER-2+) vs. Luminal A

1.65

1.01

2.71

0.046

Therapy cycle

≥ 7 vs<7

2.25

1.04

4.85

0.039

CEA (ng/mL)

≥ 2.93 vs<2.93

2.29

0.97

5.39

0.058

CA153(U/mL)

≥ 19.14 vs<19.14

1.57

0.72

3.40

0.255

Hb

≥ 135.50 vs<135.50

0.75

0.36

1.60

0.463

WBC

≥ 6.13 vs<6.13

0.41

0.18

0.95

0.037

PLT (×10^9/L)

≥ 247.50 vs<247.50

2.27

1.04

4.93

0.038

LYM

≥ 1.64 vs<1.64

5.92

2.59

13.55

<0.001

NEU (×10^9/L)

≥ 4.70 vs<4.70

0.61

0.29

1.28

0.189

Monocyte (×10^9/L)

≥ 0.44 vs<0.44

0.48

0.20

1.16

0.102

ALB (g/L)

≥ 52.15 vs<52.15

2.62

0.48

14.28

0.265

NLR

≥ 2.02 vs. <2.02

0.13

0.05

0.34

<0.001

PLR

≥ 161.50 vs<161.50

0.17

0.08

0.39

<0.001

LMR

≥ 6.39 vs<6.39

4.34

1.84

10.26

0.001

SII

≥ 598.50 vs<598.50

0.24

0.11

0.55

0.001

  1. BC: Breast cancer; NAC: Neoadjuvant chemotherapy; pCR: Pathological complete response;
  2. OR: Odds ratio; CI: Confidence interval; IDC: Invasive ductal carcinoma; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: Human epidermal growth factor receptor-2; CEA: Carcinoembryonic antigen; CA153: Carbohydrate antigen 153: WBC: White blood cell; Hb: Hemoglobin; PLT: Platelet; LYM: Lymphocyte; ALB: Albumin; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune inflammation index.